| Analysis of efficacy | ||
| Endopoint | ||
| Median progressive-free survival, months | 15.0 m | |
| 95% Confidence interval | ||
| Median overall survival, months | 36.0 m | |
| 95% Confidence interval | ||
| Response rate, % | Number of patients | (%) |
| Complete response | 2 | 5.0 |
| Partial response | 32 | 80 |
| Stable disease | 3 | 7.5 |
| Progressive disease | 3 | 7.5 |
| RR | 85% | |
| DCR | 92.5% | |